Loading clinical trials...
Loading clinical trials...
The study will be an open label, single arm, phase I study intended to identify the safety and tolerability of "AML Cell Vaccine" given to eligible MDS RAEB-2 and AML patients who have achieved a best...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
King's College London
Collaborators
NCT06303193 · Myelodysplastic Syndromes
NCT06847867 · Myelodysplastic Syndromes
NCT06439199 · Acute Myeloid Leukemia, Myelodysplastic Syndromes, and more
NCT07216443 · Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, and more
NCT06656494 · Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS)
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions